[1]
|
Wang, P., Hu, Y.J., Qu, P.P., et al. (2022) Protein Tyrosine Phosphatase Receptor Type Z1 Inhibits the Cisplatin Resistance of Ovarian Cancer by Regulating PI3K/AKT/mTOR Signal Pathway. Bioengineered, 13, 1931-1941.
https://doi.org/10.1080/21655979.2021.2022268
|
[2]
|
Boussios, S., Mikropoulos, C., Samartzis, E., et al. (2020) Wise Management of Ovarian Cancer: On the Cutting Edge. Journal of Personalized Medicine, 10, Article No. 41. https://doi.org/10.3390/jpm10020041
|
[3]
|
Tang, Z., Li, C.W., Kang, B.X., et al. (2017) GEPIA: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses. Nucleic Acids Research, 45, W98-W102. https://doi.org/10.1093/nar/gkx247
|
[4]
|
Borley, J., Wilhelm-Benartzi, C., Brown, R., Ghaem-Maghami, S., et al. (2012) Does Tumour Biology Determine Surgical Success in the Treatment of Epithelial Ovarian Cancer? A Systematic Literature Review. British Journal of Cancer, 107, 1069-1074. https://doi.org/10.1038/bjc.2012.376
|
[5]
|
Muhanmode, Y., Wen, M.K., Maitinuri, A., et al. (2021) Curcumin and Resveratrol Inhibit Chemoresistance in Cisplatin-Resistant Epithelial Ovarian Cancer Cells via Targeting P13K Pathway. Human & Experimental Toxicology, 40, S861-S868. https://doi.org/10.1177/09603271211052985
|
[6]
|
Cheaib, B., Auguste, A. and Leary, A. (2015) The PI3K/Akt/mTOR Pathway in Ovarian Cancer: Therapeutic Opportunities and Challenges. Chinese Journal of Cancer, 34, 4-16. https://doi.org/10.5732/cjc.014.10289
|
[7]
|
Torre, L.A., Trabert, B., DeSantis, C.E., et al. (2018) Ovarian Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 284-296. https://doi.org/10.3322/caac.21456
|
[8]
|
Engelman, J.A. (2009) Targeting PI3K Signalling in Cancer: Opportunities, Challenges and Limitations. Nature Reviews Cancer, 9, 550-562. https://doi.org/10.1038/nrc2664
|
[9]
|
Siegel, R., Naishadham, D. and Jemal, A. (2012) Cancer Statistics, 2012. CA: A Cancer Journal for Clinicians, 62, 10-29. https://doi.org/10.3322/caac.20138
|
[10]
|
Liby, T.A., Spyropoulos, P., Lindner, H.B., et al. (2012) Akt3 Controls Vascular Endothelial Growth Factor Secretion and Angiogenesis in Ovarian Cancer Cells. International Journal of Cancer, 130, 532-543.
https://doi.org/10.1002/ijc.26010
|
[11]
|
Liu, J., Wu, D.-C., Qu, L.-H., et al. (2018) The Role of mTOR in Ovarian Neoplasms, Polycystic Ovary Syndrome, and Ovarian Aging. Clinical Anatomy, 31, 891-898. https://doi.org/10.1002/ca.23211
|
[12]
|
Ghoneum, A., Abdulfattah, A.Y. and Said, N. (2020) Targeting the PI3K/AKT/mTOR/NFκB Axis in Ovarian Cancer. Journal of Cellular Immunology, 2, 68-73.
|
[13]
|
Janus, J.M., O’Shaughnessy, R.F.L., Harwood, C.A. and Maffucci, T. (2017) Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas. Cancers (Basel), 9, Article No. 86.
https://doi.org/10.3390/cancers9070086
|
[14]
|
Aziz, A. Fraid, S., Qin, K., Wang, H.Q. and Liu, B. (2018) PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer. Biomolecules, 8, 7. https://doi.org/10.3390/biom8010007
|
[15]
|
Mabuchi, S., Kuroda, H., Takahashi, R. and Sasano, T. (2015) The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Ovarian Cancer. Gynecologic Oncology, 137, 173-179. https://doi.org/10.1016/j.ygyno.2015.02.003
|
[16]
|
Cui, L.L., Bao, H.C., Liu, Z.F., et al. (2020) hUMSCs Regulate the Differentiation of Ovarian Stromal Cells via TGF-β(1)/Smad3 Signaling Pathway to Inhibit Ovarian Fibrosis to Repair Ovarian Function in POI Rats. Stem Cell Research & Therapy, 11, Article No. 386. https://doi.org/10.1186/s13287-020-01904-3
|
[17]
|
Deng, J., Bai, X.P., Feng, X.J., et al. (2019) Inhibition of PI3K/Akt/mTOR Signaling Pathway Alleviates Ovarian Cancer Chemoresistance through Reversing Epithelial-Mesenchymal Transition and Decreasing Cancer Stem Cell Marker Expression. BMC Cancer, 19, Article No. 618. https://doi.org/10.1186/s12885-019-5824-9
|
[18]
|
Uruski, P., Mikula-Pietrasik, J., Pakula, M., et al. (2021) Malignant Ascites Promote Adhesion of Ovarian Cancer Cells to Peritoneal Mesothelium and Fibroblasts. International Journal of Molecular Sciences, 22, Article No. 4222.
https://doi.org/10.3390/ijms22084222
|
[19]
|
雷燕, 吴绪峰. CD_(44)基因在卵巢癌中的表达及其与预后的关系[J]. 医学综述, 2013, 19(1): 155-158.
|
[20]
|
黄丽珊, 卢碧燕, 李仲均, 黄素然, 王静文. CD44v6在卵巢上皮性肿瘤中的表达及其对卵巢癌细胞株侵袭和迁移能力的影响[J]. 现代肿瘤医学, 2016, 24(4): 625-629.
|
[21]
|
Si, X., Xu, F.X., Xu, F.H., et al. (2020) CADM1 Inhibits Ovarian Cancer Cell Proliferation and Migration by Potentially Regulating the PI3K/Akt/mTOR Pathway. Biomedicine & Pharmacotherapy, 123, Article ID: 109717.
https://doi.org/10.1016/j.biopha.2019.109717
|
[22]
|
van der Ploeg, P., Uittenboogaard, A., Thijs, A.M.J., et al. (2021) The Effectiveness of Monotherapy with PI3K/AKT/ mTOR Pathway Inhibitors in Ovarian Cancer: A Meta-Analysis. Gynecologic Oncology, 163, 433-444.
https://doi.org/10.1016/j.ygyno.2021.07.008
|
[23]
|
Sobočan, M., Bračič, S., Knez, J., et al. (2020) The Communication between the PI3K/AKT/mTOR Pathway and Y-Box Binding Protein-1 in Gynecological Cancer. Cancers (Basel), 12, 205. https://doi.org/10.3390/cancers12010205
|
[24]
|
Ediriweera, M.K., Tennekoon, K.H. and Samarakoon, S.R. (2019) Role of the PI3K/AKT/mTOR Signaling Pathway in Ovarian Cancer: Biological and Therapeutic Significance. Seminars in Cancer Biology, 59, 147-160.
https://doi.org/10.1016/j.semcancer.2019.05.012
|
[25]
|
Lengyel, C.G., Altuma, S.C., Habeeb, B.S., et al. (2020) The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas. Current Drug Targets, 21, 946-961.
https://doi.org/10.2174/1389450120666191120123612
|
[26]
|
Ghoneum, A. and Said, N. (2019) PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics. Cancers (Basel), 11, 949. https://doi.org/10.3390/cancers11070949
|
[27]
|
Wen, W., Han, E.S., Dellinger, T.H., et al. (2020) Synergistic Anti-Tumor Activity by Targeting Multiple Signaling Pathways in Ovarian Cancer. Cancers (Basel), 12, 2586. https://doi.org/10.3390/cancers12092586
|
[28]
|
Hu, X.Q, Xia, M.H., Wang, J.B., et al. (2020) Dual PI3K/mTOR Inhibitor PKI-402 Suppresses the Growth of Ovarian Cancer Cells by Degradation of Mcl-1 through Autophagy. Biomedicine & Pharmacotherapy, 129, Article ID: 110397.
https://doi.org/10.1016/j.biopha.2020.110397
|
[29]
|
Gasparri, M.L., Bardhione, E., Ruscito, I., et al. (2017) PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track? Geburtshilfe und Frauenheilkunde, 77, 1095-1103. https://doi.org/10.1055/s-0043-118907
|
[30]
|
Liu, J., Leng, T.Y., Zhang, Q., et al. (2018) Anticancer Activity of Cucurbitacin-A in Ovarian Cancer Cell Line SKOV3 Involves Cell Cycle Arrest, Apoptosis and Inhibition of mTOR/PI3K/Akt Signaling Pathway. Journal of BUON, 23, 124-128.
|
[31]
|
Zhang, S., Leng, T.Y., Zhang, Q., et al. (2018) Sanguinarine Inhibits Epithelial Ovarian Cancer Development via Regulating Long Non-Coding RNA CASC2-EIF4A3 Axis and/or Inhibiting NF-κB Signaling or PI3K/AKT/mTOR Pathway. Biomedicine & Pharmacotherapy, 102, 302-308. https://doi.org/10.1016/j.biopha.2018.03.071
|
[32]
|
Zhang, Y. and Zhang, Y. (2018) Marsdenia Tenacissima Extract Inhibits Proliferation and Promotes Apoptosis in Human Ovarian Cancer Cells. Medical Science Monitor, 24, 6289-6297. https://doi.org/10.12659/MSM.909726
|